Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2B6, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes.
Showing 10 out of 77 products:
Human Monoclonal CYP2B6 Primary Antibody for FACS, IF - ABIN2718982
Sim, Nam, Lee, Lee, O, Joo, Liu, Han, Ki, Jeong, Lee, Lee: Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. in Archives of pharmacal research 2015
Show all 2 Pubmed References
Human Polyclonal CYP2B6 Primary Antibody for IF, IHC (p) - ABIN655056
Bunten, Liang, Pounder, Seneviratne, Osselton: OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. in Clinical pharmacology and therapeutics 2010
Show all 2 Pubmed References
The first data of several CYP2B6 polymorphisms in Roma population.
With consensus recommendations on downregulation, CYP2C (show CYP2C19 Antibodies) induction, and CYP2B6 positive control.
Genotyping of CYP2B6 may therefore be of value when assessing dose requirements in methadone maintenance treatment.
Genomic variation in CYP2B6 may explain, at least in part, severity of Neonatal Abstinence Syndrome
CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-Infected children.
This is the first study that investigated the impact of the 516 G>T polymorphism of the CYP2B6 gene among HIV-positive individuals from southern Brazil. Its clinical significance indicates the need for prospective studies in this population.
G(516)T CYP2B6 polymorphisms was associated with Bronchopulmonary Dysplasia susceptibility in Preterm Neonates.
The deficient CYP2B6 516 T allele is associated with higher efavirenz plasma drug levels and more frequent central nervous system-related symptoms.
Males with the CYP2B6 *6/*6 genotype may be less susceptible to the development of anti-tuberculosis drug-induced hepatotoxicity.
CYP2B6 interindividual variability was not significantly associated with genetic variation in CYP2B6, nor was it associated with differences in gender or ethnicity, suggesting that factors other than these are largely responsible for the wide range of variability in CYP2B6 expression and activity observed among a large group of individuals/samples.
This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described\; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.
cytochrome P450 2B6
, cytochrome P450 CYP2B30
, cytochrome P450, family 2, subfamily B, polypeptide 6
, cytochrome P450 PBD-2
, cytochrome P450, family 2, subfamily B, polypeptide 11
, cytochrome P450 2B3
, cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6
, cytochrome P450IIB3
, 1,4-cineole 2-exo-monooxygenase
, cytochrome P450 IIB1